Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 4/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6059665 | 0.84 | CTSV (0.49) | CTSVCTSLHSD11B1DHODHRARB | |
| SCHEMBL3731391 | 0.80 | BCHE (0.41) | CTSVCTSLHSD11B1CNR2DHODH | |
| SCHEMBL3724388 | 0.78 | CTSV (0.49) | CTSVCTSLHSD11B1RARBTSHR | |
| SCHEMBL3728181 | 0.78 | CTSV (0.49) | CTSVCTSLHSD11B1RARBTSHR | |
| SCHEMBL1705626 | 0.78 | KDM4E (0.46) | CTSVCTSLHSD11B1GPR3RARB | |
| SCHEMBL2382927 | 0.78 | KDM4E (0.46) | CTSVCTSLHSD11B1GPR3RARB | |
| SCHEMBL2384593 | 0.78 | KDM4E (0.46) | CTSVCTSLHSD11B1GPR3RARB | |
| SCHEMBL27618241 | 0.77 | CNR1 (0.47) | CTSVCTSLHSD11B1CNR2CNR1 | |
| SCHEMBL5418521 | 0.76 | CTSV (0.52) | CTSVCTSLHSD11B1RARBTSHR | |
| SCHEMBL18260237 | 0.75 | DNMT1 (0.46) | TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708351-B2 | Alkenes as alkyne equivalents in radical cascades terminated by fragmentations | The Florida State University Research Foundation, Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160347778-A1 | ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS | The Florida State University Research Foundation, Inc. | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347778-A1 | ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS | AOC3, OR51E2, AOC2 | CTSV 1558/4885CTSL 1798/4885HSD11B1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.